Ablynx to present RA research data at CRA Annual Scientific Meeting
February 9, 2017Ablynx will present additional data from the Phase IIb rheumatoid arthritis (RA) combination study of its anti-IL-6R Nanobody, vobarilizumab, at the Annual Scientific Meeting of the Canadian Rheumatology Association, being held from 8-11 February 2017 in Ottawa, Ontario (Canada).
The results of the study showed that in patients with active RA despite use of methotrexate, treatment with vobarilizumab (150mg q4w, 150mg q2w and 225mg q2w) had a positive impact on disease activity with a compelling safety profile.
The company will present data in two posters which will be available on the Ablynx website shortly after the conference.
